RAN Antibody (N-term) Blocking Peptide

Artikelnummer: ABT-BP6693A
Artikelname: RAN Antibody (N-term) Blocking Peptide
Artikelnummer: ABT-BP6693A
Hersteller Artikelnummer: BP6693a
Alternativnummer: ABT-BP6693A-500UG
Hersteller: Abcepta
Kategorie: Proteine/Peptide
Alternative Synonym: GTP-binding nuclear protein Ran, Androgen receptor-associated protein 24, GTPase Ran, Ras-like protein TC4, Ras-related nuclear protein, RAN, ARA24
RAN (ras-related nuclear protein) is a small GTP binding protein belonging to the RAS superfamily that is essential for the translocation of RNA and proteins through the nuclear pore complex. The RAN protein is also involved in control of DNA synthesis and cell cycle progression. Nuclear localization of RAN requires the presence of regulator of chromosome condensation 1 (RCC1). Mutations in RAN disrupt DNA synthesis. Because of its many functions, it is likely that RAN interacts with several other proteins. RAN regulates formation and organization of the microtubule network independently of its role in the nucleus-cytosol exchange of macromolecules. RAN could be a key signaling molecule regulating microtubule polymerization during mitosis. RCC1 generates a high local concentration of RAN-GTP around chromatin which, in turn, induces the local nucleation of microtubules. RAN is an androgen receptor (AR) coactivator that binds differentially with different lengths of polyglutamine within the androgen receptor. Polyglutamine repeat expansion in the AR is linked to Kennedys disease (X-linked spinal and bulbar muscular atrophy). RAN coactivation of the AR diminishes with polyglutamine expansion within the AR, and this weak coactivation may lead to partial androgen insensitivity during the development of Kennedys disease.
NCBI: 5901
UniProt: P62826
Formulierung: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Target-Kategorie: The synthetic peptide sequence used to generate the antibody AP6693a was selected from the N-term region of human RAN. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.